Arcturus Therapeutics Hits 52-Week Low at $6.72 Amid Ongoing Struggles

Arcturus Therapeutics Holdings, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.72 on November 17, 2025. This significant drop highlights the company's ongoing struggles, as it has experienced a staggering 78.8% decline in its stock price over the past year, contrasting sharply with the S&P 500's positive performance of 13.19% during the same period.
The company's financial metrics reveal a challenging landscape. With a market capitalization of USD 484 million, Arcturus has reported negative returns on equity of -10.01% and a debt-to-equity ratio of -1.07, indicating financial instability. The stock's price-to-book ratio stands at 2.10, suggesting that investors are paying a premium relative to the company's book value.

Recent quarterly results have also been disappointing, with net sales falling by 25.31% to USD 24.51 million and a pre-tax profit of USD -5.35 million, reflecting a decline of 64.11%. These figures underscore the company's consistent underperformance against market benchmarks, raising concerns about its future viability in a competitive industry.